Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity

Fig. 4

HuB6 exerts potent antitumor activities in humanized mouse models. a Schematic diagram for in vivo antibody treatment of human 4-1BB knock-in mice bearing murine colorectal cancer transplants or human PBMC-engrafted mice bearing human colorectal cancer transplants. After tumors were established, the mice were randomized into groups of 8 animals per group on day 8. Treatment with HuB6 orutomilumab was administered six times (indicated by vertical arrows) to MC38 model mice or five times to CT26 model mice. b The changes in tumor volume in the HuB6 (MC38 model: l, 0.3 mg/kg; m, 1 mg/kg; and h, 3 mg/kg. CT26 model: l, 1 mg/kg; m, 3 mg/kg; and h, 10 mg/kg) and utomilumab (MC38 model: 1 mg/kg; CT26 model: 10 mg/kg) groups. c Relative tumor weight determined by comparison with the isotype control. Tumor tissues were removed and weighed at the end of the experiment in (b). d Comparison of tumor volume after the treatment with HuB6, utomilumab and urelumab (MC38 model: 0.3 mg/kg; CT26 model: 1 mg/kg). e Relative tumor weight determined by comparison with the isotype control. Tumor tissues were removed and weighed at the end of the experiment in (d). In all panels, n = 8 biologically independent animals. Statistical analysis was performed using two-way ANOVA; *p < 0.05 compared to the isotype group, **p < 0.05 compared to the single antibody group. Error bars within the figure represent the mean ± SD

Back to article page